Top Story

PD-L1 alterations identify T-cell inflamed diffuse large B-cell lymphoma

July 17, 2019

Read the Perspective from Stephen Ansell, MD, PhD

Meeting News

ASH announces award recipients

July 15, 2019
Several distinguished leaders in hematology will be honored with awards and special lectures at this year’s ASH Annual Meeting and Exposition, scheduled for Dec…
Meeting NewsVideo

VIDEO: Early steroids may reduce severe side effects among patients who receive CAR T-cell therapy

July 13, 2019
CHICAGO — Max S. Topp, MD, head of hematology at University Hospital of Wuerzburg, Germany, spoke with HemOnc Today at ASCO Annual Meeting about a study that…
FDA News

FDA grants fast track designation to CLR 131 for diffuse large B-cell lymphoma

July 9, 2019
The FDA granted fast track designation to CLR 131 for treatment of relapsed or refractory diffuse large B-cell lymphoma. CLR 131 (Cellectar Biosciences) is a…
More Headlines »

Using the Latest Clinical Advances to Guide Your Practice: A Multidisciplinary Tumor Board

This activity is supported by an educational grant from Merck & Co., Inc.

The treatment paradigm for the management of patients with advanced cancer has changed dramatically within recent years…
More »
Meeting News

VIDEO: Meeting offers insights into application of CAR T-cell therapy for hematologic malignancies

March 12, 2018
More »
Resource Centers


Focus on Advancing Treatment for Acute Myeloid Leukemia

This activity is supported by an independent educational grant from Pfizer, Inc.

In this activity, Bruno Medieros, MD, and Farhad Ravandi-Kashini, MD, discuss recent advances in the treatment of acute…
More »